Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Announces Quarterly Earnings Results

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) released its earnings results on Thursday. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by ($0.05), Zacks reports. The firm had revenue of $1.18 billion during the quarter, compared to analysts’ expectations of $1.11 billion. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 16.13% and a net margin of 46.67%.

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

SGIOY stock opened at $9.44 on Friday. Shionogi & Co., Ltd. Unsponsored ADR has a one year low of $7.83 and a one year high of $12.00. The firm has a 50-day simple moving average of $9.17 and a two-hundred day simple moving average of $9.64. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.00 and a current ratio of 1.14. The firm has a market cap of $16.07 billion, a price-to-earnings ratio of 9.43, a PEG ratio of 3.38 and a beta of 0.08.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on SGIOY shares. Jefferies Financial Group raised Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. Zacks Research raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 15th. Three investment analysts have rated the stock with a Strong Buy rating. According to data from MarketBeat, the stock presently has a consensus rating of “Strong Buy”.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japanese pharmaceutical company headquartered in Osaka, Japan. Founded in 1878, the company researches, develops, manufactures and markets prescription medicines, with a longstanding focus on infectious diseases and specialty therapies.

Its products and development programs have included Xofluza (baloxavir marboxil), an oral treatment for influenza; Fetroja (cefiderocol), an antibiotic for certain difficult-to-treat Gram-negative bacterial infections; and medicines for central nervous system disorders, pain and other therapeutic areas.